CD274 and small cell lung carcinoma: However, across all treatment arms, including the placebo arm, patients with CPS ≥ 1 showed longer OS compared to patients with CPS < 1, indicating that PD-L1 expression might serve as a prognostic biomarker for ES-SCLC [40].